120 related articles for article (PubMed ID: 18627266)
21. Single infusion of zoledronic acid to prevent androgen deprivation therapy-induced bone loss in men with hormone-naive prostate carcinoma.
Satoh T; Kimura M; Matsumoto K; Tabata K; Okusa H; Bessho H; Iwamura M; Ishiyama H; Hayakawa K; Baba S
Cancer; 2009 Aug; 115(15):3468-74. PubMed ID: 19484786
[TBL] [Abstract][Full Text] [Related]
22. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone.
Boutsen Y; Jamart J; Esselinckx W; Devogelaer JP
J Bone Miner Res; 2001 Jan; 16(1):104-12. PubMed ID: 11149473
[TBL] [Abstract][Full Text] [Related]
23. The impact of dietary calcium intake and vitamin D status on the effects of zoledronate.
Bourke S; Bolland MJ; Grey A; Horne AM; Wattie DJ; Wong S; Gamble GD; Reid IR
Osteoporos Int; 2013 Jan; 24(1):349-54. PubMed ID: 22893357
[TBL] [Abstract][Full Text] [Related]
24. The effect of continuous oestradiol with intermittent norgestimate on bone mineral density and bone turnover in post-menopausal women.
Arrenbrecht S; Caubel P; Garnero P; Felsenberg D
Maturitas; 2004 Jul; 48(3):197-207. PubMed ID: 15207885
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of ability of biochemical markers of bone turnover to predict a response to increased doses of HRT.
Rosen HN; Parker RA; Greenspan SL; Iloputaife ID; Bookman L; Chapin D; Perlmutter I; Kessel B; Qvist P; Rosenblatt M
Calcif Tissue Int; 2004 May; 74(5):415-23. PubMed ID: 14961215
[TBL] [Abstract][Full Text] [Related]
26. Maintenance of increased bone mass after recombinant human parathyroid hormone (1-84) with sequential zoledronate treatment in ovariectomized rats.
Rhee Y; Won YY; Baek MH; Lim SK
J Bone Miner Res; 2004 Jun; 19(6):931-7. PubMed ID: 15125792
[TBL] [Abstract][Full Text] [Related]
27. Comparison of the effects of raloxifene and low-dose hormone replacement therapy on bone mineral density and bone turnover in the treatment of postmenopausal osteoporosis.
Dane C; Dane B; Cetin A; Erginbas M
Gynecol Endocrinol; 2007 Jul; 23(7):398-403. PubMed ID: 17701771
[TBL] [Abstract][Full Text] [Related]
28. Bone turnover 18 months after a single intravenous dose of zoledronic acid.
Borba VZ; Paz-Filho G; Kulak CA; Seibel MJ; Bilezikian JP
Int J Clin Pract; 2007 Jun; 61(6):1058-62. PubMed ID: 17504370
[TBL] [Abstract][Full Text] [Related]
29. Effects of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis: a multi-center, randomized, placebo-controlled clinical trial.
Liu JL; Zhu HM; Huang QR; Zhang ZL; Li HL; Qin YJ; Zhang Y; Wei DL; Lu JH; Liu H; Chen XP; Liu YJ; Ekangaki A; Zheng YM; Diez-Perez A; Harper K
Chin Med J (Engl); 2004 Jul; 117(7):1029-35. PubMed ID: 15265377
[TBL] [Abstract][Full Text] [Related]
30. Minodronic acid (ONO-5920/YM529) prevents decrease in bone mineral density and bone strength, and improves bone microarchitecture in ovariectomized cynomolgus monkeys.
Mori H; Tanaka M; Kayasuga R; Masuda T; Ochi Y; Yamada H; Kishikawa K; Ito M; Nakamura T
Bone; 2008 Nov; 43(5):840-8. PubMed ID: 18718565
[TBL] [Abstract][Full Text] [Related]
31. Effects of zoledronate on markers of bone metabolism and subchondral bone mineral density in dogs with experimentally induced cruciate-deficient osteoarthritis.
Agnello KA; Trumble TN; Chambers JN; Seewald W; Budsberg SC
Am J Vet Res; 2005 Sep; 66(9):1487-95. PubMed ID: 16261820
[TBL] [Abstract][Full Text] [Related]
32. Effects of Intravenous Zoledronate on Bone Turnover and Bone Density Persist for at Least 11 Years in HIV-Infected Men.
Bolland MJ; Horne AM; Briggs SE; Thomas MG; Reid I; Gamble GD; Grey A
J Bone Miner Res; 2019 Jul; 34(7):1248-1253. PubMed ID: 30870576
[TBL] [Abstract][Full Text] [Related]
33. A single intravenous administration of zoledronic acid prevents the bone loss and mechanical compromise induced by aromatase inhibition in rats.
Gasser JA; Green JR; Shen V; Ingold P; Rebmann A; Bhatnagar AS; Evans DB
Bone; 2006 Oct; 39(4):787-95. PubMed ID: 16844441
[TBL] [Abstract][Full Text] [Related]
34. Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study.
Miller PD; Chines AA; Christiansen C; Hoeck HC; Kendler DL; Lewiecki EM; Woodson G; Levine AB; Constantine G; Delmas PD
J Bone Miner Res; 2008 Apr; 23(4):525-35. PubMed ID: 18072873
[TBL] [Abstract][Full Text] [Related]
35. A dose-finding study of zoledronate in hypercalcemic cancer patients.
Body JJ; Lortholary A; Romieu G; Vigneron AM; Ford J
J Bone Miner Res; 1999 Sep; 14(9):1557-61. PubMed ID: 10469284
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics and pharmacodynamics of a single dose of zoledronate in healthy dogs.
Martín-Jiménez T; De Lorimier LP; Fan TM; Freise KJ
J Vet Pharmacol Ther; 2007 Oct; 30(5):492-5. PubMed ID: 17803746
[No Abstract] [Full Text] [Related]
37. Pamidronate in the prevention of bone loss after liver transplantation: a randomized controlled trial.
Monegal A; Guañabens N; Suárez MJ; Suárez F; Clemente G; García-González M; De la Mata M; Serrano T; Casafont F; Tome S; Barrios C; Navasa M
Transpl Int; 2009 Feb; 22(2):198-206. PubMed ID: 18796000
[TBL] [Abstract][Full Text] [Related]
38. Better late than never? Experience with intravenous pamidronate treatment in patients with low bone mass or fractures following cardiac or liver transplantation.
Dodidou P; Bruckner T; Hosch S; Haass M; Klar E; Sauer P; Ziegler R; Leidig-Bruckner G
Osteoporos Int; 2003 Jan; 14(1):82-9. PubMed ID: 12577189
[TBL] [Abstract][Full Text] [Related]
39. Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study.
Boonen S; Orwoll ES; Wenderoth D; Stoner KJ; Eusebio R; Delmas PD
J Bone Miner Res; 2009 Apr; 24(4):719-25. PubMed ID: 19049326
[TBL] [Abstract][Full Text] [Related]
40. Vitamin K supplementation does not significantly impact bone mineral density and biochemical markers of bone in pre- and perimenopausal women.
Volpe SL; Leung MM; Giordano H
Nutr Res; 2008 Sep; 28(9):577-82. PubMed ID: 19083462
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
